AbbVie Inc. last reported quarterly results on Oct 5, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $17.4 billion (+10.3% year over year) and diluted EPS of $2.37. It usually reports 3–7 days after a quarter ends. Based on that pattern, the next release is estimated for around Jan 6, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Wednesday. Based on last year's release for the same quarter on Jan 7, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 3–7 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Oct 5, 2026
5 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
17,404
+10.3%
|
4,218
+2167.7%
|
2.37
+2270.0%
|
|
Jul 6, 2026
6 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
16,990
+10.2%
|
3,613
+285.2%
|
2.03
+290.4%
|
|
Apr 3, 2026
3 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
15,002
+12.4%
|
695
-46.0%
|
0.39
-45.8%
|
|
Jan 7, 2026
7 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
16,618
+10.0%
|
1,816
+8354.5%
|
1.02
+5200.0%
|
|
Oct 3, 2025
3 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
15,776
+9.1%
|
186
-88.1%
|
0.10
-88.6%
|
|
Jul 3, 2025
3 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
15,423
+6.6%
|
938
-31.5%
|
0.52
-32.5%
|
|
Apr 3, 2025
3 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
13,343
+8.4%
|
1,286
-6.1%
|
0.72
-6.5%
|
|
Jan 6, 2025
6 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
15,102
+5.6%
|
-22
-102.7%
|
-0.02
-104.3%
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ABBV (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- North Chicago, IL
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1551152
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
- Pfizer Inc PFE
Source: SEC EDGAR filings. This is company-reported data, not investment advice.